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MaOBJECTIVES The aim of this study was to describe the role of contrast-enhanced cardiac magnetic resonance (CMR) in
the workup of patients with aborted sudden cardiac arrest (SCA) and in the prediction of long-term outcomes.
BACKGROUND Myocardial ﬁbrosis is a key substrate for SCA, and late gadolinium enhancement (LGE) on a CMR study
is a robust technique for imaging of myocardial ﬁbrosis.
METHODS We performed a retrospective review of all survivors of SCA who were referred for CMR studies and
performed follow-up for the subsequent occurrence of an adverse event (death and appropriate deﬁbrillator therapy).
RESULTS After a workup that included a clinical history, electrocardiogram, echocardiography, and coronary angiogram,
137 patients underwent CMR for workup of aborted SCA (66% male; mean age 56  11 years; left ventricular
ejection fraction 43  12%). The presenting arrhythmias were ventricular ﬁbrillation (n ¼ 105 [77%]) and ventricular
tachycardia (n ¼ 32 [23%]). Overall, LGE was found in 98 patients (71%), with an average extent of 9.9  5% of the left
ventricular myocardium. CMR imaging provided a diagnosis or an arrhythmic substrate in 104 patients (76%), including
the presence of an infarct-pattern LGE in 60 patients (44%), noninfarct LGE in 21 (15%), active myocarditis in 14 (10%),
hypertrophic cardiomyopathy in 3 (2%), sarcoidosis in 3, and arrhythmogenic cardiomyopathy in 3. In a median follow-up
of 29 months (range 18 to 43 months), there were 63 events. In a multivariable analysis, the strongest predictors of
recurrent events were the presence of LGE (adjusted hazard ratio: 6.7; 95% CI: 2.38 to 18.85; p < 0.001) and the extent
of LGE (hazard ratio: 1.15; 95% CI: 1.11 to 1.19; p < 0.001).
CONCLUSIONS Among patients with SCA, CMR with contrast identiﬁed LGE in 71% and provided a potential
arrhythmic substrate in 76%. In follow-up, both the presence and extent of LGE identiﬁed a group at markedly increased
risk of future adverse events. (J Am Coll Cardiol Img 2015;8:414–23) © 2015 by the American College of Cardiology
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AB BR E V I A T I O N S
AND ACRONYM S
ATP = antitachycardia pacing
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415are the 2 most common arrhythmias detected
among survivors of SCA (5–7). Myocardial scar is a
key substrate for the generation and maintenance of
malignant ventricular arrhythmias (8–10). TissueSEE PAGE 424
CMR = cardiac magnetic
resonance
ECG = electrocardiogram
ICD = implantable
cardioverter-deﬁbrillator
LGE = late gadolinium
enhancement
LVEF = left ventricular
ejection fraction
MACE = major adverse
cardiac events
MI = myocardial infarction
RV = right ventricle/ventricular
SCA = sudden cardiac arrest
VF = ventricular ﬁbrillation
VT = ventricular tachycardiacharacterization and the identiﬁcation of myocardial
scar using late gadolinium enhancement (LGE) are
key strengths of cardiac magnetic resonance (CMR)
(11,12). There are limited data testing the role of
CMR in the workup of survivors of SCA (4). Therefore,
our ﬁrst goal was to add to this limited data set and
test the role of the unique tissue characterization pro-
vided by CMR in the workup of survivors of SCA.
Furthermore, myocardial scar by LGE has been shown
to identify the origin of ventricular arrhythmias
(10,13), and LGE has been shown to be a key predictor
of subsequent adverse events in patients with
implantable cardioverter-deﬁbrillators (ICDs) placed
for primary prevention of sudden cardiac death
(14–16). Survivors of SCA are at signiﬁcantly increased
risk of subsequent adverse cardiac events, with a
mortality rate approaching 10% per year despite ICD
insertion (5,6,17). However, there are no data testing
the role of the presence and extent of LGE for predic-
tion of subsequent adverse events among survivorsFIGURE 1 Groups Separated According to Final Diagnosis
Acute
A ﬂow diagram of all 147 patients categorized into each of the major di
HCM ¼ hypertrophic cardiomyopathy; LGE ¼ late gadolinium enhancemof SCA. Therefore, in a second aim, we
wanted to test the role of the presence and
extent of LGE for the prediction of subse-
quent adverse events among survivors of
SCA. Our hypothesis was that a CMR study
through detection of LGE would identify a
potential arrhythmic substrate among survi-
vors of SCA and that the presence and extent
of LGE would be a discriminator of subse-
quent adverse events after ICD insertion.
METHODS
STUDY POPULATION. We conducted a com-
bination prospective and retrospective study.
We prospectively collected data on consecu-
tive patients resuscitated from SCA who
underwent a CMR study and performed a
retrospective follow-up for adverse events.
SCA was deﬁned as the sudden cessation of
effective cardiac mechanical activity, resulting in
unresponsiveness without normal breathing or signs
of circulation (18). Studies were performed between
2005 and 2011 at the Brigham and Women’s Hospital
and Massachusetts General Hospital. The CMR study
was requested after a workup that included clinicalagnostic groups. CMR ¼ cardiac magnetic resonance;
ent; MI ¼ myocardial infarction; SCA ¼ sudden cardiac arrest.
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angiogram that did not reveal a clear etiology for the
SCA. We excluded patients diagnosed with acute
myocardial infarction (MI) or who underwent revas-
cularization at the time of admission. A prior MI was
deﬁned as either clinical evidence of an MI per elec-
tronic medical records or ECG evidence deﬁned by
Minnesota codes 1.1.1 to 1.2.8 (19). Medications were
recorded at the time of discharge from the hospital.
The protocol was approved by the Human Subjects
Review Committee of both hospitals.
CMR PROTOCOL. All images were acquired with ECG
gating, breath-holding, and the patient in a supine
position, as previously described (16). Subjects were
imaged on either a 1.5-T or 3.0-T CMR system (Signa
CV/I HDXt platform, General Electric Healthcare,
Waukesha, Wisconsin, or Tim Trio, Siemens, Erlan-
gen, Germany, respectively). Both CMR protocols
consisted of cine steady-state free precession imaging
for cardiac function and LGE imaging for myocardial
ﬁbrosis (16,20–22). All images were analyzed with
specialized software (Mass Research, UniversityTABLE 1 Baseline Patient Characteristics According to the Presence o
Cohort
(n ¼ 137)
Age, yrs 56  12
Male 90 (66)
Diabetes 28 (20)
Hypertension 31 (23)
Atrial ﬁbrillation 40 (29)
History of myocardial infarction 28 (20)
Ventricular ﬁbrillation 105 (77)
Ventricular tachycardia 32 (23)
SCA to CMR, months 0.10 (0.05–0.25)
CMR to ICD, months 0.10 (0.05–0.25)
BMI, kg/m2 29  7
Systolic blood pressure, mm Hg 115  16
Diastolic blood pressure, mm Hg 70  10
Heart rate, beats/min 71  13
Medications
ACEI/ARB 107 (78)
Beta-blocker 128 (93)
Spironolactone 20 (15)
Diuretic 30 (22)
Antiarrhythmic 19 (14)
Warfarin 18 (13)
Aspirin 40 (29)
Statin 44 (62)
QRS duration, ms 113  30
QTc duration, ms 448  30
GFR, ml/min/1.73 m2 71  18
Values are mean  SD, n (%), or median (interquartile range).
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin II receptor block
ﬁltration rate; ICD ¼ implantable cardioverter-deﬁbrillator; LGE ¼ late gadolinium enhaMedical Centre, Leiden, the Netherlands) by re-
searchers blinded to clinical outcomes (16).
LATE GADOLINIUM ENHANCEMENT. LGE was con-
sidered present only if conﬁrmed on both short-axis
and matching long-axis myocardial locations. The
presence and pattern of LGE was conﬁrmed by 2 level
3 CMR experts blinded to all other clinical data. LGE
was quantiﬁed by using regions deﬁned as more than
50% of maximal signal intensity of the enhanced
area (full width at half maximum [FWHM]) (16). The
extent of LGE was not quantiﬁed at the time of the
original CMR study and was quantiﬁed retrospec-
tively by investigators blinded to all other clinical
details. The distribution of LGE was characterized as
subendocardial, transmural, mid-wall, epicardial, or
focal/involving the right ventricular (RV) insertion
points. If more than 1 pattern was present, the dis-
tribution was characterized on the basis of the pre-
dominant pattern.
METHODS OF CLINICAL FOLLOW-UP. Major adverse
cardiac events (MACE) were deﬁned as a composite ofr Absence of LGE
LGE Negative
(n ¼ 39)
LGE Positive
(n ¼ 98) p Value
56  12 56  13 0.88
32 (82) 58 (59) 0.05
6 (15) 22 (22) 0.36
10 (25) 21 (21) 0.82
10 (25) 30 (31) 0.54
11 (28) 17 (17) 0.79
36 (92) 69 (70) 0.05
5 (13) 27 (27) 0.05
0.10 (0.05–0.25) 0.13 (0.05–0.25) 0.42
0.15 (0.05–0.25) 0.07 (0.05–0.25) 0.08
30  5 29  7 0.69
114  15 116  17 0.36
69  12 71  10 0.54
72  16 71  11 0.80
29 (74) 78 (80) 0.18
38 (97) 90 (92) 1.00
7 (18) 13 (13) 0.60
9 (23) 21 (21) 1.00
4 (10) 15 (15) 0.43
4 (10) 14 (14) 0.59
12 (31) 28 (28) 1.00
14 (36) 30 (31) 0.67
110  28 118  33 0.19
447  31 451  26 0.42
73  16 71  19 0.44
er; BMI ¼ body mass index; CMR ¼ cardiac magnetic resonance; GFR ¼ glomerular
ncement; SCA ¼ sudden cardiac arrest.
TABLE 2 CMR Measurements of Entire Cohort Stratiﬁed According to the
Presence or Absence of LGE
Cohort
(n ¼ 137)
LGE Negative
(n ¼ 39)
LGE Positive
(n ¼ 98) p Value
CMR
LVEDV, ml 189  44 188  41 190  45 0.88
LVEDV index, ml/m2 98  25 97  25 98  26 0.89
LVESV, ml 111  42 108  42 112  41 0.60
LVESV index, ml/m2 57  22 56  24 58  22 0.66
LVEF, % 43  12 44  14 42  11 0.35
LV mass, g 151  48 148  50 157  44 0.30
LV mass index, g/m2 77  26 76  27 81  24 0.34
RVEDV, ml 151  53 151  53 151  53 0.96
RVEDV index, ml/m2 77  27 75  27 78  27 0.61
RVESV, ml 85  43 81  36 87  45 0.40
RVESV index, ml/m2 44  21 40  18 45  23 0.18
RVEF, % 45  12 47  11 45  12 0.35
LGE
LGE 96 (70) 0 (0) 98 (100)
LGE FWHM (% of LV mass) 9.9  5.0
LGE location
Subendocardial 46 (47)
Transmural 20 (20)
Epicardial 8 (8)
Mid-myocardial 23 (23)
Focal/insertion points 1 (1)
Values are mean  SD or n (%).
FWHM ¼ full width at half maximum; LV ¼ left ventricular; LVEDV ¼ left ventricular
end-diastolic volume; LVEF ¼ left ventricular ejection fraction; LVESV ¼ left ventricular
end-systolic volume; RV ¼ right ventricular; RVEDV ¼ right ventricular end-diastolic volume;
RVEF ¼ right ventricular ejection fraction; RVESV ¼ right ventricular end-systolic volume; other
abbreviations as in Table 1.
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417all-cause mortality and appropriate ICD intervention.
An appropriate ICD intervention was deﬁned as either
antitachycardia pacing (ATP) or an ICD shock and was
classiﬁed as appropriate if the intervention was a
result of ventricular tachyarrhythmia according to
established criteria (23). Adjudication of ICD events
were performed by 2 cardiac electrophysiologists
(S.B.D. and M.T.) blinded to all other clinical data.
Mortality was ascertained using the Social Security
Death Index and conﬁrmed using electronic chart
review and, if necessary, contact with the primary
provider. Patients were followed at 3- to 6-month
intervals via clinic visits or, if appropriate, trans-
mitted ICD data. Survival analyses were performed
for the composite endpoint. The duration of follow-
up was determined from the CMR study date to the
occurrence of an endpoint or the date of the last
clinical follow-up. Patients were censored at the date
of the last clinical follow-up.
STATISTICAL ANALYSIS. Continuous data are pre-
sented as mean  SD or median (interquartile range).
Categorical data are presented as number and per-
centages. Continuous data were compared with the
use of unpaired Student t tests or Wilcoxon rank-sum
tests when appropriate. Categorical data were
compared using the Fisher exact test. The hazard
ratio for the prediction of the events was calculated
for MACE using Cox regression models. We used 2
Cox regression models, and each model contained
risk markers associated with adverse outcomes; these
included age, sex, history of diabetes, left ventricular
ejection fraction (LVEF) and LV end-diastolic volume.
In the ﬁrst model, we included the presence of LGE;
in the second, we included the extent of LGE. To ﬁnd
the best overall multivariable model for the compos-
ite endpoint, we used a stepwise-backward selection
with a probability to remove the effect from the
regression at p > 0.05. The proportional-hazards
assumption was met in all models, and all models ﬁt
the data well. Event curves were determined ac-
cording to the Kaplan-Meier method, and compari-
sons of cumulative event rates were performed by the
log-rank test. A receiver-operating characteristic
(ROC) curve was constructed to determine the
optimal value with the maximum sensitivity and
speciﬁcity of LGE extent to predict adverse cardio-
vascular events. Stata/SE 10.0 was used for the sta-
tistical analysis (version 10.0, StataCorp LP, College
Station, Texas).
RESULTS
The number of patients referred for a CMR study for
workup of SCA was 147 (Figure 1). From these 147patients, there were 137 with a diagnosis that was not
clear before the CMR study (Table 1). The presenting
arrhythmias were VF (n ¼ 105 [77%]) and VT (n ¼ 32
[23%]). The average LVEF was 43  12% and RVEF was
45  12% (Table 2). Of the entire cohort, 96 patients
(70%) had an LVEF of <50% at the time of CMR.
LATE GADOLINIUM ENHANCEMENT. LGE was pres-
ent in 98 patients (71%) (Table 2). The LGE pattern
was subendocardial in 46 (47%), transmural in 20
(21%), mid-myocardial in 23 (23%), epicardial in 8
(8%), and at the insertion point of the RV in 1 of the
patients (1%). The average extent of LGE was 9.9  5%
of the LV myocardium. Patients were grouped
according to the presence or absence of LGE (Tables 1
and 2). VT was more commonly the presenting
arrhythmia in patients with LGE, and VF was more
common in those without LGE. There was a higher
percentage of men in the LGE-negative group;
otherwise, there were no signiﬁcant differences
between patients with and without LGE.
IDENTIFICATION OF AN ARRHYTHMIC SUBSTRATE.
Among the 137 patients who were referred for a
contrast CMR study for workup of SCA, a diagnosis or
FIGURE 2 CMR Provides a Diagnosis or Potential Arrhythmic Source
A ﬂow diagram showing how the information from a contrast CMR study can provide a key ﬁnding or diagnosis. ARVC ¼ arrhythmogenic right
ventricular cardiomyopathy; other abbreviations as in Figure 1.
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418potential arrhythmic substrate was identiﬁed in 104
patients (76%). The abnormalities included the pres-
ence of an infarct-pattern LGE in 60 patients (44%),
noninfarct LGE in 21 (19%), active myocarditis in
14 (10%), hypertrophic cardiomyopathy in 3 (2%),
sarcoidosis in 3, and arrhythmogenic cardiomyopathy
in 3. There were 26 patients with a prior clinical or
ECG diagnosis of a remote MI. Among these 26 pa-
tients, a non-MI pattern of LGE was identiﬁed in 19%,
an MI pattern of LGE was identiﬁed in 42%, and no
LGE was identiﬁed in 39% (Figure 2).
CLINICAL FOLLOW-UP. All patients underwent ICD
placement. The median follow-up was 29 months
(interquartile range: 18 to 43 months). There were 63
subsequent adverse events among the 137 patients.
These events included death in 16 patients and
an appropriate ICD intervention in 47 patients. The
appropriate ICD interventions included ICD dis-
charge in 26 patients and 21 pace-terminated events.
There were 7 events among the 41 patients without
LGE (event rate of 7% per year) and 56 events amongthe 96 patients with LGE (event rate of 23% per year)
(Tables 3 and 4). The 7 adverse events in LGE-
negative patients consisted of 2 deaths (LVEF 15%
and 45% at time of CMR), 2 appropriate ICD dis-
charges (LVEF 31% and 62% at the time of CMR), and
3 ATP discharges (LVEF 28%, 38%, and 25%). The
initial event in an LGE-negative patient was an ATP
event after 13 months, and the 2 deaths occurred
at 53 and 68 months of follow-up. During follow-up
of the patients with LGE, there were 34 VT events
and 8 VF events compared with 4 VT events and 1 VF
event among the LGE-negative patients. There were
23 inappropriate ICD discharges overall, and this
included 13 among the 41 patients without LGE and
10 among the 96 patients with LGE. The study cohort
also consisted of 10 patients with angiographically
signiﬁcant coronary artery disease (>50% narrowing
in the distribution of a major epicardial vessel).
Among these 10 patients, 6 had LGE and 4 did not
have LGE. We repeated the event analysis after
stratifying based on the LVEF by CMR. There were
48 events among the 96 patients with an LVEF <50%
TABLE 4 Characteristics of Patients With and Without Subsequent MACE
No MACE
(n ¼ 74)
MACE
(n ¼ 63) p Value
CMR
LVEDV, ml 189  43 190  46 0.89
LVEDV index, ml/m2 96  24 100  26 0.39
LVESV, ml 111  43 111  41 0.96
LVESV index, ml/m2 57  22 58  23 0.65
LVEF, % 43  13 43  11 0.98
LV mass, g 145  46 156  50 0.18
LV mass index, g/m2 76  25 79  27 0.42
RVEDV, ml 150  54 152  52 0.82
RVEDV index, ml/m2 75  29 79  25 0.37
RVESV, ml 83  41 88  45 0.46
RVESV index, ml/m2 42  21 46  21 0.23
RVEF, % 46  11 45  12 0.62
LGE 40 (54) 56 (89) <0.001
LGE extent (FWHM) 5.7  2.3 12.8  4.2 <0.001
LGE location
Subendocardial 28 (70) 18 (32) <0.001
Transmural 7 (18) 13 (23) 0.61
Epicardial 1 (2) 7 (13) 0.13
Mid-myocardial 4 (8) 19 (32) <0.01
Insertion point 1 (2) 0 (0) 0.42
Values are mean  SD or n (%).
Abbreviations as in Tables 1 and 2.
TABLE 3 Characteristics of Patients With and Without Subsequent MACE
No MACE
(N ¼ 74)
MACE
(N ¼ 63) p Value
Age, yrs 56  12 56  12 0.72
Male 48 (65) 42 (67) 0.86
Diabetes 13 (18) 15 (24) 0.40
Hypertension 18 (24) 13 (21) 0.68
Prior myocardial infarction 14 (19) 14 (22) 0.68
Atrial ﬁbrillation 18 (24) 22 (35) 0.19
Medications
Aspirin 21 (28) 19 (30) 0.85
Beta-blocker 67 (91) 61 (97) 0.18
ACEI/ARB 57 (77) 50 (79) 0.84
Spironolactone 10 (14) 10 (16) 0.81
Diuretic 13 (18) 17 (27) 0.22
Statin 26 (35) 18 (29) 0.47
Anticoagulant 8 (11) 10 (16) 0.45
BMI, kg/m2 30  5 28  8 0.12
Systolic blood pressure, mm Hg 116  15 115  18 0.76
Diastolic blood pressure, mm Hg 70  11 70  10 0.87
Heart rate, beats/min 73  13 70  12 0.27
QRS duration, ms 112  32 114  29 0.67
QTc duration, ms 446  29 451  30 0.31
GFR, ml/min/1.73 m2 74  16 68  20 0.06
Values are mean  SD or n (%).
MACE ¼ major adverse cardiac events; other abbreviations as in Table 1.
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419(event rate 20%/year); in comparison, there were 15
events among the 41 patients with an LVEF >50%
(event rate 15%/year).
UNIVARIABLE AND MULTIVARIABLE ASSOCIATIONS
WITH MACE. In the initial Cox model, which con-
tained variables associated with adverse outcomes
and the presence of LGE, we found that the presence
of LGE provided the strongest association with
adverse outcomes (Tables 5 and 6). In a second model,
which contained variables associated with adverse
outcomes and the extent of LGE, we found that the
extent of LGE provided the strongest association with
adverse outcomes (Tables 7 and 8). A ROC curve
among patients with LGE was generated to determine
what extent of LGE could help identify a group at
further increased risk of MACE (Figure 3). Analysis of
the ROC curve revealed that a percentage of LGE by
volume of $8.1% using the FWHM method (area
under the curve 0.89; sensitivity 90%; speciﬁcity
80%) maximized the sum of sensitivity and speciﬁcity
for prediction of events. Kaplan-Meier curves gener-
ated for event-free survival among patients by both
the binary presence or absence of LGE and the extent
of LGE are presented (Figure 4). Patients with an LGE
extent $8.1% represented a subgroup at very high
risk of subsequent adverse events. In this subgroup
with an LGE extent of $8.1%, there were 45 events,
or a cumulative event rate of more than 78%. In
comparison, among patients with an LGE extent
of <6.8%, there were 5 events, or a cumulative event
rate of 9%.
DISCUSSION
In this study, we showed the additive value of a
contrast CMR study in survivors of SCA, especially
when an initial workup was unrevealing. Speciﬁcally,
we showed how the presence and pattern of LGE was
valuable in the diagnostic workup of patients who
survive a cardiac arrest. The presence of LGE identi-
ﬁed a potential arrhythmic substrate among 76%
of patients among whom a workup involving clinical
assessment, ECG, echocardiogram, and coronary an-
giogram did not show a clear cause of arrest. Among
these, most had an unrecognized infarct, followed by
scar related to prior or active myocarditis, scar related
to dilated cardiomyopathy, or unrecognized hyper-
trophic cardiomyopathy, sarcoidosis, or arrhyth-
mogenic cardiomyopathy. The study also tested the
predictors of subsequent adverse events among pa-
tients who survived SCA and found that almost 45%
of patients either died or had appropriate ICD therapy
in follow-up and that the presence and the extent of
TABLE 7 Multivariable Model for MACE
Hazard Ratio SE p Value 95% CI
LGE extent (FWHM) 1.15 0.02 <0.001 1.11–1.19
Age 1.01 0.01 0.25 0.99–1.04
Male 1.17 0.34 0.59 0.66–2.09
LVEF 1.01 0.01 0.63 0.98–1.04
Diabetes 0.91 0.29 0.78 0.48–1.72
LVEDV 1.00 0.00 0.51 1.00–1.01
Abbreviations as in Tables 1, 2, 3, 5 and 6.
TABLE 5 Multivariable Model for MACE
Hazard Ratio SE p Value 95% CI
LGE 6.70 3.54 <0.001 2.38–18.85
Age 0.99 0.02 0.66 0.96–1.02
Male 1.70 0.57 0.11 0.89–3.28
LVEF 1.00 0.02 0.77 0.97–1.04
Diabetes 1.02 0.36 0.95 0.52–2.03
LVEDV 1.00 0.00 0.43 1.00–1.01
CI ¼ conﬁdence interval; other abbreviations as in Tables 1 and 2.
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formation among this high-risk cohort.
White et al. (4) tested the diagnostic yield of CMR
among 30 patients with resuscitated SCA. The study
structure was different in that all patients with
resuscitated SCA underwent CMR in comparison with
our study in which CMR was not protocol based and
patients were referred for CMR only after the initial
workup did not reveal a clear etiology. In the study
by White et al. (4) they performed a clinical assess-
ment, ECG, echocardiogram, and assessment of cor-
onary anatomy in a consecutive series of patients
with an SCA. After this assessment, the cause of SCA
was unclear in 50%. They next performed a contrast
CMR study and in the 50% of patients in whom the
etiology of the SCA was unclear, CMR provided a
diagnosis in 74%. That diagnosis varied but included
an MI in over one-third of patients. We extended the
ﬁndings of White et al. (4) and tested the role of CMR
in a large cohort of survivors of SCA. In our study
containing 137 patients with resuscitated SCA
without a clear diagnosis before CMR, we found that
CMR provided an arrhythmic substrate in more than
75% of patients. Indeed, a large percentage of the
diagnosis involved unrecognized myocardial in-
farcts. This ﬁnding of an unrecognized myocardial
infarct is in keeping with prior work among “healthy
subjects” (24), patients with known coronary disease
free of recognized MI (25), patients with diabetes
(26), and patients with atrial ﬁbrillation (22), showing
that unrecognized MIs are a relatively frequent
occurrence with a clear prognostic effect. The ﬁnding
of an unrecognized MI in patients free of signiﬁcantTABLE 6 Multivariable Model for MACE: Stepwise Cox
Regression (Exclusion Criteria p > 0.05)
Hazard Ratio SE p Value 95% CI
LGE 6.25 3.28 <0.001 2.24–17.47
SE ¼ standard error; other abbreviations as in Tables 1, 3, and 5.coronary disease and presenting with SCA is new. In
patients with a similar mean LVEF and presumed
ischemic cardiomyopathy, LGE is found in close to
100% (27). However, in patients with presumed
nonischemic cardiomyopathy, LGE is found in an
ischemic distribution in 20% (27), leading to the hy-
pothesis that the presence of LGE in angiographically
normal coronary arteries may be a marker for in-
creased risk of SCA.
The implantation of an ICD is warranted in all,
and ICDs improve survival among patients resusci-
tated from SCA (5–7,17). In the AVID (Antiarrhyth-
mics Versus Implantable Deﬁbrillators) study, 68%
of patients either died or had secondary therapy
at 2 years (28). Similarly, among a large population
of patients who survived SCA, approximately 40%
either died or required appropriate ICD therapy at
2 to 3 years (29). In our study, the cumulative event
rate was 45% among all patients resuscitated from
SCA. However, there are no prior data testing the
role of LGE on future outcomes among patients
resuscitated from SCA. In a complementary study,
Dawson et al. (30) tested the role of LGE among a
cohort of patients with nonsustained and sustained
VT. In that study, the mean LVEF was 60%, one-
third underwent ICD insertion, and one-third had
LGE. The pattern of LGE was nonischemic in two-
third and ischemic in one-third. They found that
the presence of LGE provided stronger prognostic
information than LVEF. Among patients with resus-
citated SCA, we found that both the presence and
the extent of LGE were associated with a markedly
increased rate of subsequent adverse events. ThereTABLE 8 Multivariable Model for MACE: Stepwise Cox
Regression (Exclusion Criteria p > 0.05)
Hazard Ratio SE p Value 95% CI
LGE extent (FWHM) 1.14 0.02 <0.001 1.10–1.19
Abbreviations as in Tables 1, 2, 3, 5 and 6.
FIGURE 3 ROC Curve for LGE Extent and the Prediction of MACE
Receiver-operating curve (ROC) testing LGE extent as a predictor of major adverse cardiac
events (MACE). Analysis revealed that the percentage of LGE by volume of $8.1% pro-
vided the maximal combination of sensitivity and speciﬁcity. FWHM ¼ full width at half
maximum; other abbreviation as in Figure 1.
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421are no randomized data among any cohort showing
that an intervention based on LGE can improve
outcomes. Therefore, an extension of this work
would test whether intervention based on the pres-
ence or extent of LGE, either via medications, ICD
programming (31), or advance electrophysiological
(32) techniques, can reduce the frequency of ICD
discharge or death. For example, in this study, a
small number of patients were prescribed pharma-
cological antiarrhythmic therapy on discharge, and
future studies could test whether antiarrhythmic
therapy at discharge could reduce the rate of recur-
rent events.
STUDY LIMITATIONS. This study should be inter-
preted within the context of the design format. This
was a cohort of patients resuscitated from SCA who
were referred for a CMR study as a workup for
structural causes of arrhythmias. We did not include
all patients successfully resuscitated from SCA, and
the decision to perform a CMR study was at the
discretion of the primary physician and not part of an
institutional protocol. We agree that this lack of a
standardized and protocol-driven approach leads to a
signiﬁcant selection bias. Furthermore, CMR pro-
tocols, magnet strength, and ICD programming varied
across institutions and across time and were not
identical for all patients. This was not a multicenter
study and only involved 2 centers. However, we
believe that our cohort is representative of priorFIGURE 4 Event-Free Survival Separated According to the Presence and Extent of LGE
Kaplan-Meier curves displaying event-free survival in cohorts according to (A) the dichotomous presence or absence of LGE and (B) an extent of LGE of $8.1% or <8.1%
of the volume of the left ventricle. Abbreviation as in Figure 1.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Among patients with SCA, a CMR study of the heart
with contrast identiﬁes scar in the heart in 71% and
provides a potential arrhythmic substrate in 76%
of patients. Furthermore, both the presence and
extent of scar are markers that identify survivors of
SCA who are markedly increased risk of future adverse
events.
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422studies among patients resuscitated from SCA. Spe-
ciﬁcally, 3 secondary prevention randomized con-
trolled trials have reported cardiac function in
survivors of SCA randomized to ICD versus medical
therapy. In the AVID study, the mean LVEF was
32% (7), whereas, in the CIDS (Canadian Implantable
Deﬁbrillator Study) trial, which enrolled a similar
study cohort, the mean LVEF was 34% (5). In the
CASH (Cardiac Arrest Study Hamburg) study, the
mean LVEF was 45% (6), similar to that reported in
an observational population study of survivors of
SCA (33). Our study cohort consisted of patients who
were broadly similar. We found a mean LVEF of 41%
and a similar presenting arrhythmia. This study does
not provide mechanistic insight into the cause of the
ischemic pattern of LGE, but possibilities include
vasospasm, embolism, myocarditis, and occult pla-
que rupture (34). We also recorded the medical
therapy at the time of discharge; therefore, how
therapy was modiﬁed over time was not captured
and how the presence of LGE inﬂuenced therapy is
unknown.TRANSLATIONAL OUTLOOK: Additional studies
are needed to validate the ﬁndings and test whether
the routine performance of CMR in survivors of SCA
may be of diagnostic use in broad populations and test
whether the information provided by CMR can help
guide therapies to prevent subsequent adverse out-
comes in survivors of SCA.CONCLUSIONS
Among patients resuscitated from SCA who were
referred for CMR study, we found that a contrast CMR
study provided added value, especially among
patients in whom the diagnosis was unclear after an
initial standard workup.ACKNOWLEDGMENTS The authors thank the CMR
technologists at both institutions for continued
excellence.
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